Literature DB >> 15964949

Anti-Plasmodium vivax duffy binding protein antibodies measure exposure to malaria in the Brazilian Amazon.

Isabela P Cerávolo1, Oscar Bruña-Romero, Erika M Braga, Cor J F Fontes, Cristiana F A Brito, José M Souza, Antoniana U Krettli, John H Adams, Luzia H Carvalho.   

Abstract

Plasmodium vivax Duffy binding protein (DBP) is functionally important in the erythrocyte invasion process and provides a logical target for vaccine-mediated immunity. In the current study, we demonstrated that DBP is naturally immunogenic in different populations of the Brazilian Amazon, and the proportions of DBP IgG positive subjects increased with exposure to malaria, reaching a peak in those subjects with long-term exposure (> 15 years) in the Amazon area. This profile of antibody response was significantly different from the one observed for the P. vivax merozoite surface protein 1 (MSP1(19)), which was relatively uniform in areas with markedly different levels of malaria transmission. In a small sample of adults with symptomless P. vivax infection, we could not detect any significant correlation between antibodies against these P. vivax proteins and asymptomatic infection. Our study provided an additional insight by demonstrating cumulative exposure as a determinant that acts independently of host age in generation of anti-DBP IgG response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964949

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  25 in total

1.  Antibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmission.

Authors:  Sedigheh Zakeri; Laleh Babaeekhou; Akram Abouie Mehrizi; Maryam Abbasi; Navid Dinparast Djadid
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.

Authors:  Ana Carolina Rios Silvino; Flora Satiko Kano; Marcelo Azevedo Costa; Cor Jesus Fernandes Fontes; Irene Silva Soares; Cristiana Ferreira Alves de Brito; Luzia Helena Carvalho; Tais Nobrega Sousa
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

3.  Evaluation of the naturally acquired antibody immune response to the Pv200L N-terminal fragment of Plasmodium vivax merozoite surface protein-1 in four areas of the Amazon Region of Brazil.

Authors:  Luciane M Storti-Melo; Wanessa C Souza-Neiras; Gustavo C Cassiano; Leonardo C Taveira; Antônio J Cordeiro; Vanja S C A Couto; Marinete M Póvoa; Maristela G Cunha; Diana M Echeverry; Andréa R B Rossit; Myriam Arévalo-Herrera; Sócrates Herrera; Ricardo L D Machado
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

4.  B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon.

Authors:  J C Lima-Junior; J Jiang; R N Rodrigues-da-Silva; D M Banic; T M Tran; R Y Ribeiro; V S E Meyer; S G De-Simone; F Santos; A Moreno; J W Barnwell; M R Galinski; J Oliveira-Ferreira
Journal:  Vaccine       Date:  2011-01-06       Impact factor: 3.641

5.  Plasmodium vivax circumsporozoite genotypes: a limited variation or new subspecies with major biological consequences?

Authors:  Wanessa C Souza-Neiras; Luciane M Storti-Melo; Gustavo C Cassiano; Vanja S C A Couto; Alvaro A R A Couto; Irene S Soares; Luzia H Carvalho; Maristela G Cunha; Marinete M Póvoa; Socrates Herrera; Myriam A Herrera; Andrea R M Rossit; Claudia M A Carareto; Ricardo L D Machado
Journal:  Malar J       Date:  2010-06-23       Impact factor: 2.979

6.  Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.

Authors:  Francis B Ntumngia; Samantha J Barnes; Amy M McHenry; Miriam T George; Jesse Schloegel; John H Adams
Journal:  Clin Vaccine Immunol       Date:  2014-06-25

7.  Duffy Blood Group System and the malaria adaptation process in humans.

Authors:  Gledson Barbosa de Carvalho; Glauber Barbosa de Carvalho
Journal:  Rev Bras Hematol Hemoter       Date:  2011

8.  Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques.

Authors:  A Moreno; I Caro-Aguilar; S S Yazdani; A R Shakri; S Lapp; E Strobert; H McClure; C E Chitnis; M R Galinski
Journal:  Vaccine       Date:  2008-06-23       Impact factor: 3.641

9.  Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection.

Authors:  I P Ceravolo; B A M Sanchez; T N Sousa; B M Guerra; I S Soares; E M Braga; A M McHenry; J H Adams; C F A Brito; L H Carvalho
Journal:  Clin Exp Immunol       Date:  2009-06       Impact factor: 4.330

10.  Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals.

Authors:  J C Lima-Junior; T M Tran; E V S Meyer; B Singh; S G De-Simone; F Santos; C T Daniel-Ribeiro; A Moreno; J W Barnwell; M R Galinski; J Oliveira-Ferreira
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.